Skip to content

IGM Biosciences

  • About Us
    • Our Company
    • Leadership Team
  • IGM Platform
    • Our IGM Platform
    • Publications
    • Presentations
  • Pipeline & Programs
    • Pipeline
    • IGM-2323
    • IGM-2644
    • IGM-8444
    • IGM-7354
  • Investors & News
  • Join Us
    • Our Culture
    • Open Jobs
  • Contact Us
Presentations
  • 2022
  • 2021
  • 2020
  • 2019
April 2022

AACR 2022: A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas

American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022

Read more
April 2022

AACR 2022: High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing

American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022

Read more
April 2022

AACR 2022: Enhanced NK and CD8+ T cell proliferation, tumor cytotoxicity and reversal of T cell exhaustion with IGM-7354, an anti-PD-L1 IgM antibody and IL-15 cytokine fusion

American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022

Read more
April 2022

AACR 2022: Anti-DR5 agonist IgM antibody IGM-8444 combined with SMAC mimetic birinapant induces strong synergistic tumor cytotoxicity

American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022

Read more

All content © IGM Biosciences, Inc.    info@igmbio.com    Site Credits

LinkedIn